Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence
- PMID: 17760809
- DOI: 10.1111/j.1365-2141.2007.06738.x
Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence
Abstract
Measurement of the thrombin generating potential could provide a method for quantifying the composite effect of multiple risk factors. This study assessed the risk of a first as well as a recurrent venous thrombotic event associated with an increased endogenous thrombin potential (ETP). Analyses were performed in 360 patients and 404 control subjects of the Leiden Thrombophilia Study. The ETP was measured directly using a fluorogenic assay (Thrombinoscope). Individuals with an increased ETP, i.e. above 90th percentile measured in control subjects (>2109.0 nM x min) had a 1.5-fold [95% confidence interval (CI): 0.9-2.3] increased risk of a first deep venous thrombosis. The risk was more pronounced after the analysis was restricted to idiopathic thromboses, i.e. 1.7-fold (95% CI: 1.0-2.8). Overall, the hazard ratio of a recurrent thrombotic event associated with a high ETP, adjusted for age, sex and oral anticoagulant use was 1.1 (95% CI: 0.5-2.2). Thus, a high ETP was not associated with an increased relative risk of recurrent venous thrombosis. At present, the clinical relevance of the thrombin generation assay in predicting recurrent venous thrombosis remains uncertain.
Similar articles
-
Thrombin generation in patients after acute deep-vein thrombosis.Thromb Haemost. 2008 Aug;100(2):240-5. Thromb Haemost. 2008. PMID: 18690343 Clinical Trial.
-
The endogenous thrombin potential and the risk of venous thromboembolism.Thromb Res. 2007;121(3):353-9. doi: 10.1016/j.thromres.2007.04.012. Epub 2007 Jun 8. Thromb Res. 2007. PMID: 17560633
-
Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years.Thromb Haemost. 2011 Nov;106(5):901-7. doi: 10.1160/TH11-04-0254. Epub 2011 Sep 22. Thromb Haemost. 2011. PMID: 21947267
-
Venous thromboembolism: risk factors for recurrence.Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):298-310. doi: 10.1161/ATVBAHA.108.182428. Arterioscler Thromb Vasc Biol. 2009. PMID: 19228602 Review.
-
Prolonged clot lysis time increases the risk of a first but not recurrent venous thrombosis.Br J Haematol. 2016 Mar;172(6):947-53. doi: 10.1111/bjh.13911. Epub 2016 Jan 15. Br J Haematol. 2016. PMID: 26773756 Review.
Cited by
-
Elevated activated partial thromboplastin time-based clot waveform analysis markers have strong positive association with acute venous thromboembolism.Biochem Med (Zagreb). 2019 Jun 15;29(2):020710. doi: 10.11613/BM.2019.020710. Biochem Med (Zagreb). 2019. PMID: 31223264 Free PMC article.
-
Low Thrombin Generation in Users of a Contraceptive Containing Estetrol and Drospirenone.J Clin Endocrinol Metab. 2022 Dec 17;108(1):135-143. doi: 10.1210/clinem/dgac511. J Clin Endocrinol Metab. 2022. PMID: 36099501 Free PMC article.
-
A thrombin-driven neural net diagnoses the antiphospholipid syndrome without the need for interruption of anticoagulation.Blood Adv. 2024 Feb 27;8(4):936-946. doi: 10.1182/bloodadvances.2023011938. Blood Adv. 2024. PMID: 38163323 Free PMC article.
-
HIV infection is associated with decreased thrombin generation.Clin Infect Dis. 2012 Apr;54(8):1196-203. doi: 10.1093/cid/cis014. Clin Infect Dis. 2012. PMID: 22438347 Free PMC article.
-
Combined oral contraceptives containing estradiol valerate vs ethinylestradiol on coagulation: A randomized clinical trial.Acta Obstet Gynecol Scand. 2022 Oct;101(10):1102-1111. doi: 10.1111/aogs.14428. Epub 2022 Jul 31. Acta Obstet Gynecol Scand. 2022. PMID: 35909329 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical